Melvedok

Moxifloxacin, the active ingredient in Melvedok, is a fluoroquinolone antibiotic presented as an oral formulation for oral use. It treats a range of bacterial infections, including respiratory and skin infections, in adult patients as prescribed by a healthcare professional and is commonly employed in community‑acquired infections.

GNH USA supplies Melvedok as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance. Our distribution network ensures timely delivery across multiple regions.

Moxifloxacin is indicated for several bacterial infections affecting the respiratory tract and skin.

Community‑acquired pneumonia: effective treatment of bacterial lung infection in adults. Acute bacterial sinusitis: eradicates the causative pathogens in sinus inflammation. Acute bacterial exacerbation of chronic bronchitis: reduces bacterial load during flare‑ups. Skin and soft tissue infections: combats Gram‑positive and Gram‑negative organisms in cutaneous lesions.

Moxifloxacin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools, usually self‑limiting. - Headache: transient cranial discomfort. - Dizziness: occasional vertigo. - Rash: mild skin erythema. - Photosensitivity: increased sun sensitivity.

Serious or Rare Side Effects: - Tendon rupture: especially Achilles tendon, may occur without warning. - QT interval prolongation: risk of cardiac arrhythmias. - Severe allergic reactions: anaphylaxis, angioedema. - Clostridioides difficile‑associated diarrhea: potentially life‑threatening colitis. - Hepatic injury: elevated liver enzymes or hepatitis. - Peripheral neuropathy: numbness or tingling in extremities.

When prescribing Moxifloxacin, clinicians should consider several safety precautions to minimize risk.

Assess renal and hepatic function: adjust use in patients with impairment. Avoid in patients with known QT interval prolongation: may increase arrhythmia risk. Use with caution in elderly: higher incidence of tendon disorders. Review allergy history: contraindicated in patients with fluoroquinolone hypersensitivity. Monitor for tendon pain or swelling: discontinue if symptoms appear. Store at ambient temperature below 25°C: keep in original packaging, protect from moisture.

Moxifloxacin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concurrent use with other fluoroquinolones: additive toxicity. - Co‑administration with drugs that prolong QT interval (e.g., quinidine, sotalol, azithromycin): increased risk of cardiac arrhythmias. - Combination with antacids or supplements containing aluminum, magnesium, calcium, or iron: reduces absorption of moxifloxacin.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, monitor INR. - Theophylline: may increase plasma levels, watch for toxicity. - Cyclosporine: may raise cyclosporine concentrations, adjust dose as needed.